灯盏细辛注射液和灯盏花素片的临床-化学成分对比研究  

Comparing Erigerontis injection with Breviscapine tablet on the clinical and chemical constituents

作　　者：杨文宇[1] 张艺[1] 张静[1] 

机构地区：[1]成都中医药大学,四川成都610075

出　　处：《华西药学杂志》2005年第4期298-300,共3页West China Journal of Pharmaceutical Sciences

基　　金：国家自然科学基金(批准号:30271581)

摘　　要：目的通过对灯盏细辛两种主要制剂的分析,探讨灯盏细辛注射液在治疗心脑血管疾病方面的物质基础。方法采用文献分析和HPLC分析的方法。结果灯盏细辛注射液与灯盏花素片有相同的临床用途和截然不同的化学成分;提出了可用于中药疗效物质基础研究的“临床—化学”新研究模式。结论咖啡酰衍生物和灯盏花素都是灯盏细辛注射液治疗心脑血管和眼科疾病的有效成分。OBJECTIVE To investigate the active compounds of Erigeron breviscapus for curing cadiocerebral disease by analyzing Erigerontis injection and Breviscapine tablet. METHODS Literature - analysis and HPLC analysis were used. RESULTS Erigerontis injection and Breviseapine tablet have completely different constituents but with identical indications. A novel pattern for research on herbal active constituents was developed as Clinic - chemistry model. CONCLUSION Caffeoyl derivate and breviscapine are both active constituents in E. breviscapus for cardiocerebral and optic desease.

关 键 词：灯盏细辛 灯盏花素 有效成分 临床-化学研究模式 文献分析 HPLC 

分 类 号：R284.1[医药卫生—中药学] R285.6[医药卫生—中医学]